Biden Health Care Enforcement Priorities

Biden Health Care Enforcement Priorities

Client Alert

Related Solutions

We help companies protect data, comply with evolving regulations, and respond to investigations and litigation.
With litigators who previously served as senior lawyers in the Departments of Justice and Defense, and in-house for a major defense contractor, our team has successfully represented clients in difficult, high-stakes FCA litigation brought by relators and the government.
Named an “FCPA Powerhouse” and “Practice Group of the Year,” we have been involved in some of the most notable public and non-public cases and key developments related to FCPA and anti-corruption issues.
Drawing on years of experience in the public and private sectors, our lawyers handle a range of litigation involving the federal government, state and foreign governments, and complex regulatory regimes.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Guiding clients through high-stakes and sensitive investigations.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A global team handling highly complex and sensitive matters in all aspects of litigation.
Critical industry insight and formidable strength across key practices.

The Biden Administration is expected to devote significant resources to investigating fraud and abuse in the health care industry. Not only will the Biden Administration likely continue investigating traditional health care priorities, but it likely will exercise heightened scrutiny over the use of funds relating to the COVID-19 pandemic and other current issues, such as nursing home care and the opioid epidemic. We also anticipate additional resources devoted to these investigations overall. In this alert, we outline each of the Biden Administration’s most likely enforcement priorities in this industry.

Read the full alert here. 

Authors

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel